Trends, Costs, and Complications of Anterior Cervical Discectomy and Fusion With and Without Bone Morphogenetic Protein in the United States Medicare Population

Elizabeth L Lord; Jeremiah R Cohen; Zorica Buser; Hans-Joerg Meisel; Darrel S Brodke; S Tim Yoon; Jim A Youssef; Jeffrey C Wang; Jong-Beom Park

doi:10.1177/2192568217699207

Trends, Costs, and Complications of Anterior Cervical Discectomy and Fusion With and Without Bone Morphogenetic Protein in the United States Medicare Population

Global Spine J. 2017 Oct;7(7):603-608. doi: 10.1177/2192568217699207. Epub 2017 Aug 17.

Authors

Elizabeth L Lord¹, Jeremiah R Cohen¹, Zorica Buser², Hans-Joerg Meisel³, Darrel S Brodke⁴, S Tim Yoon⁵, Jim A Youssef⁶, Jeffrey C Wang², Jong-Beom Park⁷

Affiliations

¹ University of California at Los Angeles, Los Angeles, CA, USA.
² University of Southern California, Los Angeles, CA, USA.
³ Bergmannstrost Hospital, Halle, Germany.
⁴ University of Utah School of Medicine, Salt Lake City, UT, USA.
⁵ Emory Spine Center, Atlanta, GA, USA.
⁶ Durango Orthopedic Associates, P.C./Spine Colorado, Durango, CO, USA.
⁷ Uijongbu St. Mary's Hospital, Catholic University of Korea School of Medicine, Uijongbu, Korea.

Abstract

Study design: Retrospective database review.

Objectives: After the Food and Drug Administration approved bone morphogenetic protein-2 (BMP) in 2002, BMP was used off-label in the cervical spine to increase bone growth and bony fusion. Since then, concerns have been raised regarding complication rates and safety. This study was conducted to examine the use of BMP in anterior cervical discectomy and fusion (ACDF) in the Medicare population and to determine risk of complications and associated costs within 90 days of surgery.

Methods: Patients who underwent ACDF were identified using Current Procedural Terminology (CPT) and International Classification of Diseases, Ninth Revision Procedure codes (ICD9-P). Complications were identified using ICD9 diagnostic codes. Charges were calculated as amount billed, and reimbursements were calculated as amounts paid by Medicare. Data for these analyses came from a nationwide claims database.

Results: A total of 215 047 patients were identified who had ACDF from 2005 to 2011. For the majority of the procedures (89.0%), BMP was not used. BMP use rose from 11.84% in 2005 to a peak of 16.73% in 2007 before decreasing to 12.01% in 2011. BMP was used 16% more in women than men. BMP use was the highest in the West (13.6%) followed by Midwest (11.8%), South (10.6%), and Northeast (7.5%). There was a higher overall complication rate in the BMP group (2.1%) compared with the non-BMP group (1.9%) (odds ratio [OR] = 1.11, 95% CI = 1.01-1.22). The BMP group also had a higher rate of wound complications (0.98% vs 0.76%, OR = 1.29, 95% CI = 1.12-1.48). In this study population, there was no difference in dysphagia/hoarseness, neurologic, medical, or other complications. During the 90-day perioperative period, BMP surgeries were charged at 17.6% higher than non-BMP surgeries.

Conclusions: The use of BMP in ACDF in the Medicare population has decreased since a peak in 2007. The rate of wound and overall complications for BMP use with ACDF was higher than without. Our results regarding dysphagia/hoarseness did not show a statistically meaningful difference, which is in contrast with many other studies. Charges associated with BMP use were higher during the 90-day perioperative period.

Keywords: anterior cervical discectomy and fusion; bone morphogenetic protein; trends.

Publication types

Review